Eterna Therapeutics INC 10-Q quarterly reports

Ernexa Therapeutics reported increased R&D expenses and a net loss for the six months ended June 30, 2026, while also addressing Nasdaq listing requirements and advancing its ERNA-101 program.

Ernexia Therapeutics reports increased R&D expenses and a significant goodwill impairment in Q1 2026, alongside progress in financing and Nasdaq compliance efforts.

Ernexa Therapeutics Inc. reported a reduced net loss for Q3 2025, driven by cost efficiencies and a recent $7.2 million capital raise, but faces substantial doubt about its ability to continue as a going concern.

Ernexa Therapeutics Inc. reported a reduced net loss and lower cash burn in Q2 2025, bolstered by a $7.2 million private placement, but faces substantial doubt about its ability to continue as a going concern.

Ernexa Therapeutics reports a net loss of $8.2 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while also announcing a new securities purchase agreement.

Eterna Therapeutics reports a net loss of $38.8 million for the nine months ended September 30, 2024, but completes a significant debt restructuring and regains compliance with Nasdaq listing requirements.

Eterna Therapeutics reported a net loss of $5.5 million for the second quarter of 2024 and faces substantial doubt about its ability to continue as a going concern due to insufficient cash reserves.

Eterna Therapeutics reported a net loss of $6.6 million for the first quarter of 2024 and faces substantial doubt about its ability to continue as a going concern.